Predictive, Preventive and Personalised Medicine as the Medicine of the Future: Anticipatory Scientific Innovation and Advanced Medical Services

  • Olga GolubnitschajaEmail author
  • Vincenzo Costigliola


Depending on innovation in medical services and healthcare systems as a whole, two potential scenarios are considered. A pessimistic scenario considers the pandemic of type 2 diabetes mellitus and the dramatic increase of neurological disorders, CVD and cancer diseases, with severe economic consequences to the society. The optimistic scenario considers integrated concepts of early, so-called predictive diagnostics, targeted preventive measures, and treatments tailored to the person as the future of healthcare. Global research and implementation programs in bio-medicine, communication amongst scientific entities, healthcare providers, policy-makers, educators, and patient organisations, together with consolidation of professional groups in the field of personalised medicine, will play a decisive role in driving the situation towards one of the two scenarios. PPPM concepts aim to promote the optimistic scenario in Europe and worldwide. The long-term strategies of the European Association for Predictive, Preventive and Personalised Medicine towards scientific and technological innovation as well as advanced medical services are described.


Anticipation Advanced healthcare Predictive preventive personalised medicine (PPPM) Scientific and technological innovation 


  1. 1.
    George, B., Cebioglu, M., Yeghiazaryan, K.: Inadequate diabetic care: global figures cry for preventive measures and personalized treatment. EPMA J. 1, 13–18 (2010)CrossRefGoogle Scholar
  2. 2.
    Golubnitschaja, O.: Time for new guidelines in advanced diabetes care: paradigm change from delayed interventional approach to predictive, preventive & personalized medicine. EPMA J. 1, 3–12 (2010)CrossRefGoogle Scholar
  3. 3.
    Golubnitschaja, O., Swanton, C., Danesi, R., Costigliola, V.: Promoting predictive, preventive and personalised medicine: European event of global importance. EPMA J. 2, 131–136 (2011)CrossRefGoogle Scholar
  4. 4.
    Golubnitschaja, O.: Time for new guidelines in advanced healthcare: the mission of the EPMA journal to promote an integrative view in predictive, preventive and personalized medicine. EPMA J. 3, 5 (2012)Google Scholar
  5. 5.
    Society for Participatory Medicine.
  6. 6.
    Golubnitschaja, O., Costigliola, V.: EPMA.: general report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European association for predictive, preventive and personalised medicine. EPMA J. 3, 14 (2012)CrossRefGoogle Scholar
  7. 7.
    Golubnitschaja, O., Watson, I.D., Topic, E., Sandberg, S., Ferrari, M., Costigliola, V.: Position paper of the EPMA and EFLM: a global vision of the consolidated promotion of an integrative medical approach to advance health care. EPMA J. 4, 12 (2013)CrossRefGoogle Scholar
  8. 8.
    Andrews, R.J.: Global medical knowledge, local medical implementation: predictive, preventive, and personalised medicine. In: Andrews, R.J. Too Big Succeed—Profiteering in American Medicine, pp. 124–127. iUniverse, Bloomington (2013)Google Scholar
  9. 9.
    Costigliola, V. (ed.): Healthcare Overview—New Perspectives. Springer (2012)Google Scholar
  10. 10.
    Redig, A.J., McAllister, S.S.: Breast cancer as a systemic disease: a view of metastasis. J. Intern. Med. 274, 113–126 (2013)CrossRefGoogle Scholar
  11. 11.
    Cox, T.R., Rumney, R.M.H., Schoof, E.M., Perryman, L., Høye, A.M., Agrawal, A., Bird, D., Latif, N.A., Forrest, H., Evans, H.R., Huggins, I.D., Lang, G., Linding, R., Gartland, A., Erler, J.T.: The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 522, 106–110 (2015)CrossRefGoogle Scholar
  12. 12.
    Golubnitschaja, O., Sridhar, K.C.: Liver metastatic disease: New concepts and biomarker panels to improve individual outcomes Clin. Exp. Metastasis (2016). doi: 10.1007/s10585-016-9816-8
  13. 13.
    Grech, G., Zhan, X., Yoo, B.C., Bubnov, R., Hagan, S., Danesi, R., Vittadini, G., Desiderio, D.M.: EPMA position paper in cancer: current overview and future perspectives. EPMA J. 6, 9 (2015)CrossRefGoogle Scholar
  14. 14.
    Golubnitschaja, O., Debald, M., Yeghiazaryan, K., Kuhn, W., Pešta, M., Costigliola, V., Grech, G.:  Breast cancer epidemic in the early 21st century: Evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures. Tumor Biol. (2016). doi: 10.1007/s13277-016-5168-x
  15. 15.
    Iso, H.: Promoting predictive, preventive and personalized medicine in treatment of cardiovascular diseases. EPMA J. 2, 1–4 (2011)CrossRefGoogle Scholar
  16. 16.
    Helms, T.M., Duong, G., Zippel-Schultz, B., Tilz, R.R., Kuck, K.-H., Karle, C.A.: Prediction and personalised treatment of atrial fibrillation-stroke prevention: consolidated position paper of CVD professionals. EPMA J. 5, 15 (2014)CrossRefGoogle Scholar
  17. 17.
    Mozaffari, M.S. (ed.): New Strategies to Advance Pre/Diabetes Care: Integrative Approach by PPPM. Springer (2013)Google Scholar
  18. 18.
    Golubnitschaja, O., Yeghiazaryan, K., Cebioglu, M., Morelli, M., Herrera-Marschitz, M.: Birth asphyxia as the major complication in newborns: moving towards improved individual outcomes by prediction, targeted prevention and tailored medical care. EPMA J. 2, 197–210 (2011)CrossRefGoogle Scholar
  19. 19.
    Borisow, N., Döring, A., Pfueller, C.F., Paul, F., Dörr, J., Hellwig, K.: Expert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancy. EPMA J. 3, 9 (2012)CrossRefGoogle Scholar
  20. 20.
    Mähler, A., Mandel, S., Lorenz, M., Ruegg, U., Wanker, E.E., Boschmann, M., Paul, F.: Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases? EPMA J. 4, 5 (2013)CrossRefGoogle Scholar
  21. 21.
    Mandel, S. (ed.): Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future. Springer (2013)Google Scholar
  22. 22.
    Özgüç, M. (ed.): Rare Diseases—Integrative PPPM Approach as the Medicine of the Future. Springer (2015)Google Scholar
  23. 23.
    Roberti di Sarsina, P., Iseppato, I.: Why we need integrative medicine. EPMA J. 2, 5–7 (2011)Google Scholar
  24. 24.
    Roberti di Sarsina, P., Alivia, M., Guadagni, P.: Traditional, complementary and alternative medical systems and their contribution to personalisation, prediction and prevention in medicine-person-centred medicine. EPMA J. 3, 15 (2012)Google Scholar
  25. 25.
    Wang, W., Russell, A., Yan, Y.: Global health epidemiology reference group (GHERG): traditional Chinese medicine and new concepts of predictive, preventive and personalized medicine in diagnosis and treatment of suboptimal health. EPMA J. 5, 4 (2014)CrossRefGoogle Scholar
  26. 26.
    Bubnov, R.V.: Evidence-based pain management: is the concept of integrative medicine applicable? EPMA J. 3, 13 (2012)CrossRefGoogle Scholar
  27. 27.
    Cafiero, C., Matarasso, S.: Predictive, preventive, personalised and participatory periodontology: “the 5Ps age” has already started. EPMA J. 4, 16 (2013)CrossRefGoogle Scholar
  28. 28.
    Golubnitschaja, O., Costigliola, V.: Dental health: EPMA recommendations for innovative strategies. EPMA J. 5, A119 (2014)CrossRefGoogle Scholar
  29. 29.
    Kunin, A.A., Moiseeva, N.S.: A novel approach for detection of primary tooth caries based on the light influence foundation. EPMA J. 5, A123 (2014)CrossRefGoogle Scholar
  30. 30.
    Trovato, G.M.: Behavior, nutrition and lifestyle in a comprehensive health and disease paradigm: skills and knowledge for a predictive, preventive and personalized medicine. EPMA J. 3, 8 (2012)CrossRefGoogle Scholar
  31. 31.
    Shapira, N.: Women’s higher health risks in the obesogenic environment: a gender nutrition approach to metabolic dimorphism with predictive, preventive, and personalised medicine. EPMA J. 4, 1 (2013)CrossRefGoogle Scholar
  32. 32.
    Oja, P., Titze, S.: Physical activity recommendations for public health: development and policy context. EPMA J. 2, 253–259 (2011)CrossRefGoogle Scholar
  33. 33.
    Graf, C.: Preventing and treating obesity in pediatrics through physical activity. EPMA J. 2, 261–270 (2011)CrossRefGoogle Scholar
  34. 34.
    Alivia, M., Guadagni, P., Roberti di Sarsina, P.: Towards salutogenesis in the development of personalised and preventive healthcare. EPMA J. 2, 381–384 (2011)Google Scholar
  35. 35.
    Younesi, E., Hofmann-Apitius, M.: From integrative disease modeling to predictive, preventive, personalized and participatory (P4) medicine. EPMA J. 4, 23 (2013)CrossRefGoogle Scholar
  36. 36.
    Drucker, E., Krapfenbauer, K.: Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. EPMA J. 4, 7 (2013)CrossRefGoogle Scholar
  37. 37.
    Lemke, H.U., Golubnitschaja, O.: Towards personal health care with model-guided medicine: long-term PPPM-related strategies and realisation opportunities within “Horizon 2020”. EPMA J. 5, 8 (2014)CrossRefGoogle Scholar
  38. 38.
    Berliner, L., Lemke, H.U. (eds.): An Information Technology Framework for Predictive, Preventive and Personalised Medicine: A Use-Case with Hepatocellular Carcinoma. Springer (2015)Google Scholar
  39. 39.
    Zhan, X., Desiderio, D.M.: The use of variations in proteomes to predict, prevent, and personalize treatment for clinically nonfunctional pituitary adenomas. EPMA J. 1, 439–459 (2010)CrossRefGoogle Scholar
  40. 40.
    Hu, R., Wang, X., Zhan, X.: Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer. EPMA J. 4, 2 (2013)CrossRefGoogle Scholar
  41. 41.
    Grech, G., Grossman, I. (eds.): Preventive and Predictive Genetics: Towards Personalised Medicine. Springer (2015)Google Scholar
  42. 42.
    Waerner, T., Thurnher, D., Krapfenbauer, K.: The role of laboratory medicine in healthcare: quality requirements of immunoassays, standardisation and data management in prospective medicine. EPMA J. 1, 619–626 (2010)CrossRefGoogle Scholar
  43. 43.
    Gahan, P.B. (ed.) Circulating Nucleic Acids in Early Diagnosis, Prognosis and Treatment Monitoring—An Introduction. Springer (2015)Google Scholar
  44. 44.
    Deigner, H.-P.: Challenges in biobanking in personalized medicine—a biobank society’s view. EPMA J. 5, A128 (2014)CrossRefGoogle Scholar
  45. 45.
    Mandel, S., Morelli, M., Halperin, I., Korczyn, A.: Biomarkers for prediction and targeted prevention of Alzheimer’s and Parkinson’s diseases: evaluation of drug clinical efficacy. EPMA J. 1, 273–292 (2010)CrossRefGoogle Scholar
  46. 46.
    Colley, K.J., Wolfert, R.L., Cobble, M.E.: Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk. EPMA J. 2, 27–38 (2011)CrossRefGoogle Scholar
  47. 47.
    Yap, T.A., Swanton, C., de Bono, J.S.: Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon? EPMA J. 3, 3 (2012)CrossRefGoogle Scholar
  48. 48.
    Coelho, J.F., Ferreira, P.C., Alves, P., Cordeiro, R., Fonseca, A.C., Góis, J.R., Gil, M.H.: Drug delivery systems: advanced technologies potentially applicable in personalized treatments. EPMA J. 1, 164–209 (2010)CrossRefGoogle Scholar
  49. 49.
    Coelho, J. (ed.): Drug Delivery Systems: Advanced Technologies Potentially Applicable in Personalised Treatment. Springer, Dordrecht (2013)Google Scholar
  50. 50.
    Spivak, M.Y., Bubnov, R.V., Yemets, I.M., Lazarenko, L.M., Tymoshok, N.O., Ulberg, Z.R.: Development and testing of gold nanoparticles for drug delivery and treatment of heart failure: a theranostic potential for PPP cardiology. EPMA J. 4, 20 (2013)CrossRefGoogle Scholar
  51. 51.
    Ohno, T.: Particle radiotherapy with carbon ion beams. EPMA J. 4, 9 (2013)CrossRefGoogle Scholar
  52. 52.
    Golubnitschaja, O., Lemke, H.U., Kapalla, M., Kent, A.: Design in predictive, preventive and personalised medicine. In: Kuksa, I., Fisher, T. (eds.) Design for Personalisation. Gower Publishing, London (2016) (In press)Google Scholar
  53. 53.
    Polivka, J., Polivka, J., Karlikova, M., Topolcan, O.: Pre-graduate and post-graduate education in personalized medicine in the Czech Republic: statistics, analysis and recommendations. EPMA J. 5, 22 (2014)CrossRefGoogle Scholar
  54. 54.
    Advances in Predictive, Preventive and Personalised Medicine.
  55. 55.
    EPMA Journal.
  56. 56.
    Ausweger, C., Burgschwaiger, E., Kugler, A., Schmidbauer, R., Steinek, I., Todorov, Y., Thurnher, D., Krapfenbauer, K.: Economic concerns about global healthcare in lung, head and neck cancer: meeting the economic challenge of predictive, preventive and personalized medicine. EPMA J. 1, 627–631 (2010)CrossRefGoogle Scholar
  57. 57.
    Fischer, T., Langanke, M., Marschall, P., Michl, S. (eds.): Individualized Medicine—Ethical, Economical and Historical Perspectives. Springer, Dordrecht (2015)Google Scholar
  58. 58.
    Nadin, M.: The anticipatory profile. An attempt to describe anticipation as process. Int. J. Gen. Syst. 41(1), 43–75 (2012) (Nadin, M. (ed.), Taylor & Francis, London)Google Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Radiological ClinicBonn UniversityBonnGermany
  2. 2.European Association for Predictive, Preventive and Personalised MedicineBrusselsBelgium

Personalised recommendations